TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
NCT03856099
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class
Stopped
Subject recruitment issues and follow-up study plans
Conditions
Recurrent Glioblastoma
Interventions
DRUG:
TTAC-0001
Sponsor
PharmAbcine